Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

NCT00706992 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

50

Enrollment

NIH

Sponsor class

Stopped \<11 subjects were enrolled to each Arm

Conditions

Melanoma

Interventions

BIOLOGICAL: ALVAC-MART-1 vaccine
BIOLOGICAL: MART-1:26-35(27L) peptide vaccine
BIOLOGICAL: Aldesleukin
BIOLOGICAL: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes
BIOLOGICAL: incomplete Freund's adjuvant

Sponsor

National Cancer Institute (NCI)